Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.80 |
| ▸ | POLB | P06746 | 2/20 | 0.80 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dyphylline SCHEMBL1816552 | 0.89 | LMNA (1.00) | LMNASMN1; SMN2POLBRXFP1GAA | |
| Dyphylline SCHEMBL8192 | 0.89 | LMNA (1.00) | LMNASMN1; SMN2POLBRXFP1GAA | |
| Dyphylline SCHEMBL123781 | 0.89 | LMNA (1.00) | LMNASMN1; SMN2POLBRXFP1GAA | |
| SCHEMBL11601258 | 0.88 | LMNA (0.78) | LMNASMN1; SMN2POLBRXFP1GAA | |
| SCHEMBL10768492 | 0.88 | LMNA (0.78) | LMNASMN1; SMN2POLBRXFP1GAA | |
| SCHEMBL11757490 | 0.88 | LMNA (0.78) | LMNASMN1; SMN2POLBRXFP1GAA | |
| Dyphylline SCHEMBL27937456 | 0.88 | LMNA (0.97) | LMNASMN1; SMN2POLBRXFP1GAA | |
| SCHEMBL10853379 | 0.88 | ADORA2B (0.66) | LMNASMN1; SMN2POLBRXFP1ADORA2B | |
| SCHEMBL13944619 | 0.87 | LMNA (0.81) | LMNASMN1; SMN2POLBRXFP1GAA | |
| SCHEMBL5265296 | 0.86 | LMNA (0.81) | LMNASMN1; SMN2POLBRXFP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255920-A1 | METHOD FOR TREATING METASTATIC PROSTATE CANCER | THE WILLIAM M YARBROUGH FOUNDATION | 2023-08-17 | — | — | US | disclosed |
| US-20180030453-A1 | METHOD FOR IMPROVING LEARNING | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| US-20120052005-A1 | COMBINATION THERAPY TO IMPROVE DRUG EFFICIENCY | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030453-A1 | METHOD FOR IMPROVING LEARNING | NT5E, ADORA1, ENTPD5 | LMNA 1842/4885SMN1; SMN2 453/4885POLB 2242/4885 |
| US-20120052005-A1 | COMBINATION THERAPY TO IMPROVE DRUG EFFICIENCY | ABCG2, ABCB1, ABCC1 | LMNA 2548/4885SMN1; SMN2 1995/4885POLB 1063/4885 |
| US-20230255920-A1 | METHOD FOR TREATING METASTATIC PROSTATE CANCER | BPHL, KLK3, ACP3 | LMNA 3770/4885SMN1; SMN2 4056/4885POLB 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.